Human immune cells and pancreatic beta cells

The term 'Human immune cells and pancreatic beta cells' refers to the complex cellular interaction that defines the pathogenesis of Type 1 Diabetes (T1D). In this autoimmune condition, the immune system—specifically autoreactive T-lymphocytes and B-lymphocytes—loses self-tolerance and selectively attacks the insulin-producing beta cells within the pancreatic islets of Langerhans (Source: NIH, NIDDK). This targeted destruction leads to a critical deficiency in insulin, resulting in chronic hyperglycemia and the requirement for lifelong exogenous insulin therapy (Source: Nature Reviews Endocrinology). Therapeutic research in this area focuses on 'disease-modifying' agents that can either suppress the aggressive immune response or protect the remaining beta cell mass from further damage (Source: Lancet Diabetes & Endocrinology). For instance, the drug Teplizumab targets the CD3 receptor on T-cells to interfere with their ability to destroy beta cells, thereby delaying the progression of clinical T1D (Source: NEJM). Because this entry describes a multicellular biological system rather than a single protein, enzyme, or receptor, it is classified as an incorrect or overly broad therapeutic target designation.

Other names

Immune-beta cell axisIslet-infiltrating immune cellsT1D cellular axis

Prevention of autoimmune-mediated destruction of pancreatic beta cells through the modulation of T-cell and B-cell activity or the enhancement of beta cell resilience.